REG - Syncona Limited - FELIX trial of obe-cel meets its primary endpoint

SynconaAnnouncement

09/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221209:nRSI1409Ja&default-theme=true

RNS Number : 1409J  Syncona Limited  09 December 2022

Syncona Limited

 

Autolus announces FELIX trial of obe-cel meets its primary endpoint

 

09 December 2022

 

Syncona Ltd, a leading healthcare company focused on creating, building and
scaling global leaders in life science, notes that its portfolio company,
Autolus Therapeutics Plc (Nasdaq: AUTL) ("Autolus"), has announced that the
pivotal Phase II FELIX clinical trial in relapsed/refractory (r/r) adult Acute
Lymphoblastic Leukemia (ALL) patients has met its primary endpoint at interim
analysis. A copy of the announcement is set out below, with key highlights:

 

·   Obe-cel demonstrated an overall remission rate (ORR), the primary
endpoint for the trial, of 70% in an interim analysis of 50 patients

·   Encouraging safety data observed from a wider group of 92 patients,
with 3% of patients experiencing Grade 3 or higher cytokine release syndrome
(CRS) and 8% experiencing Grade 3 or higher immune effector cell-associated
neurotoxicity syndrome (ICANS)

·  Enrolment is now complete for the initial target (so-called
"morphological") cohort, meeting the pre-specified goal of 90 patients
enrolled, with this cohort to form the basis of a Biological License
Application (BLA) submission by the end of CY2023 to the US Food and Drug
Administration (FDA)

·   Autolus plans to present updated results from the FELIX trial at a
medical conference in mid-CY2023, with longer term follow up data to be
reported at the end of CY2023

 

The achievement of the primary endpoint milestone has triggered a $35 million
payment from Blackstone Life Sciences ("Blackstone"), with Autolus also
announcing an additional $35 million payment from Blackstone as a result of
the completion of planned activities supporting the obe-cel manufacturing
process.

 

Martin Murphy, Chief Executive Officer and Chair of Syncona Investment
Management Limited, said: "Today's announcement from Autolus marks an
important moment for the company as it progresses its lead programme of
obe-cel in adult ALL. The data is consistent with what was previously
presented in the ALLCAR19 academic study, underlining the potential of obe-cel
as a drug which can provide meaningful impact for patients suffering from ALL
whilst also showing a very positive safety profile in a last line setting. We
are also encouraged by the expansion and persistence of obe-cel and look
forward to future updates on whether this translates into potential
best-in-class clinical durability.

 

We are excited about the data announced today and look forward to seeing
further follow up data from the company in 2023 as it prepares to file a BLA
submission and moves closer towards delivering a approved medicine for
patients, thereby achieving one of Syncona's foundational long-term goals."

 

 ENDS 

 

Copies of this press release and other corporate information can be found on
the company website at: www.synconaltd.com (http://www.synconaltd.com)

 

Forward-looking statements - this announcement contains certain
forward-looking statements with respect to the portfolio of investments of
Syncona Limited. These statements and forecasts involve risk and uncertainty
because they relate to events and depend upon circumstances that may or may
not occur in the future. There are a number of factors that could cause actual
results or developments to differ materially from those expressed or implied
by these forward-looking statements. In particular, many companies in the
Syncona Limited portfolio are conducting scientific research and clinical
trials where the outcome is inherently uncertain and there is significant risk
of negative results or adverse events arising. In addition, many companies in
the Syncona Limited portfolio have yet to commercialise a product and their
ability to do so may be affected by operational, commercial and other risk

 

Enquiries

 

Syncona Ltd

 

Annabel Clark / Fergus Witt

Tel: +44 (0) 20 3981 7940

 

FTI Consulting

 

Ben Atwell / Natalie Garland-Collins / Julia Bradshaw / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

 

About Syncona

 

Syncona's purpose is to invest to extend and enhance human life. We do this by
founding and building companies to deliver transformational treatments to
patients in areas of high unmet need.

 

Our strategy is to create, build and scale companies around exceptional
science to create a diversified portfolio of 20-25 globally leading healthcare
businesses for the benefit of all our stakeholders. We focus on developing
treatments for patients by working in close partnership with world-class
academic founders and management teams. Our balance sheet underpins our
strategy enabling us to take a long-term view as we look to improve the lives
of patients with no or poor treatment options, build sustainable life science
companies and deliver strong risk-adjusted returns to shareholders.

 

Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met
primary endpoint at interim analysis

 

-     Obe-cel demonstrated Overall Remission Rate (ORR) of 70% in interim
analysis of 50 patients with relapsed/refractory (r/r) adult Acute
Lymphoblastic Leukemia (ALL)

-     Encouraging safety data observed, with 3% ≥Grade 3 Cytokine
Release Syndrome (CRS) and 8% ≥Grade 3 Immune effector cell-associated
neurotoxicity syndrome (ICANS) in 92 patients treated

-     Achievement of development milestone has triggered payment of $35m
from Blackstone Life Sciences, announced in a separate press release today

-     The trial has completed screening patients for entry into the
morphological cohort

 

LONDON, December 8, 2022 - Autolus Therapeutics plc (Nasdaq: AUTL), a
clinical-stage biopharmaceutical company developing next-generation programmed
T cell therapies, today announces that the Phase 2 pivotal FELIX clinical
trial of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult
Acute Lymphoblastic Leukemia (ALL) has met its primary endpoint, based on a
pre-planned interim analysis of 50 patients with morphological disease, as
verified by an independent data monitoring committee (IDMC). The primary
endpoint for the FELIX Phase 2 trial is the Overall Remission Rate (ORR),
defined as the proportion of patients achieving Complete Remission (CR) and
Complete Remission with Incomplete Blood Count Recovery (CRi) as assessed by
an independent response review committee (IRRC).

Based on 50 patients evaluated for efficacy, the ORR for obe-cel was 70%.
Obe-cel showed comparable expansion and initial persistence (median follow-up
6.4 months) to the data observed in the prior ALLCAR19 study. The safety
analysis was based on 92 patients treated with obe-cel and evaluable for
safety. The Company observed that 3% of patients experienced Grade 3 or higher
CRS, whilst 8% experienced Grade 3 or higher ICANS, and 23% of patients
experienced any grade ICANS.

"Obe-cel's high level of anti-leukemia activity combined with a well
manageable tolerability profile is a significant step forward in this
underserved disease setting, which is characterized by the explosive growth of
the leukemia and the poor condition of many patients," said Dr. Jae Park,
Associate Attending Physician at Memorial Sloan Kettering Cancer Center. "The
expansion and initial persistence of obe-cel are encouraging from a long-term
outcome perspective and I look forward to the next data update and the
potential of obe-cel as a treatment for ALL."

"We are really pleased with the consistency of data from the interim analysis
of the FELIX study with our prior results from the ALLCAR19 study in adult
patients with relapsed / refractory ALL," said Dr. Claire Roddie, Associate
Professor Haematology, Cancer Institute, University College London (UCL).

"We are delighted to be announcing that our first pivotal trial conducted has
met its primary endpoint based on our interim analysis, and we believe that we
are one step closer to bringing this potentially innovative treatment to an
underserved ALL patient population," said Dr. Christian Itin, Chief Executive
Officer of Autolus. "We look forward to supplementing this interim data with
longer follow up data to more fully explore the clinical benefit of obe-cel,
and to work towards the submission of a Biologics License Application (BLA) by
the end of 2023 to the U.S. Food and Drug Administration (FDA)."

"We would like to thank patients and their families, our treating physicians
and the clinical development and manufacturing teams for their trust,
commitment and determination to deliver this study during a challenging
pandemic-impacted environment."

The trial has completed screening patients for entry into the morphological
cohort as the pre-specified goal of approximately 90 patients enrolled has
been reached, and Autolus plans to present the results from the FELIX trial at
a medical conference in mid-2023, with longer follow up planned to be reported
at the end of 2023.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing
next-generation, programmed T cell therapies for the treatment of cancer.
Using a broad suite of proprietary and modular T cell programming
technologies, Autolus is engineering precisely targeted, controlled and highly
active T cell therapies that are designed to better recognize cancer cells,
break down their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information, please
visit www.autolus.com (http://www.autolus.com) .

About obe-cel (AUTO1)

Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome the
limitations in clinical activity and safety compared to current CD19 CAR T
cell therapies. Designed to have a fast target binding off-rate to minimize
excessive activation of the programmed T cells, obe-cel may reduce toxicity
and be less prone to T cell exhaustion, which could enhance persistence and
improve the ability of the programmed T cells to engage in serial killing of
target cancer cells. In collaboration with Autolus' academic partner, UCL,
obe-cel is currently being evaluated in a Phase 1 clinical trial for B-NHL.
Autolus has progressed obe-cel to the FELIX trial, a pivotal trial for r/r
adult ALL.

About obe-cel FELIX clinical trial

Autolus' Phase 1b/2 clinical trial of obe-cel is enrolling adult patients with
r/r B-precursor ALL. The trial had a Phase 1b component prior to proceeding to
the single arm, Phase 2 clinical trial. The primary endpoint is ORR, and the
secondary endpoints include duration of response, minimal residual disease
(MRD) negative CR rate and safety. The trial is designed to enroll
approximately 100 patients across 30 of the leading academic and non-academic
centers in the United States, United Kingdom, and Europe.  NCT04404660 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are statements that are not historical
facts, and in some cases can be identified by terms such as "may," "will,"
"could," "expects," "plans," "anticipates," and "believes." These statements
include, but are not limited to, statements regarding the continued
development of Autolus' obe-cel program including timing of and expectations
regarding planned readouts, expectations that the final data set will be
confirmatory of the data from the interim analysis and the planned submission
of a Biologics License Application by the end of 2023. Any forward-looking
statements are based on management's current views and assumptions and involve
risks and uncertainties that could cause actual results, performance, or
events to differ materially from those expressed or implied in such
statements. These risks and uncertainties include, but are not limited to, the
risks that Autolus' preclinical or clinical programs do not advance or result
in approved products on a timely or cost effective basis or at all; the
results of early clinical trials are not always being predictive of future
results; the cost, timing, and results of clinical trials; that many product
candidates do not become approved drugs on a timely or cost effective basis or
at all; the ability to enroll patients in clinical trials; possible safety and
efficacy concerns; and the impact of the ongoing COVID-19 pandemic on Autolus'
business. For a discussion of other risks and uncertainties, and other
important factors, any of which could cause Autolus' actual results to differ
from those contained in the forward-looking statements, see the section titled
"Risk Factors" in Autolus' Annual Report on Form 20-F filed with the
Securities and Exchange Commission on March 10, 2022, as well as discussions
of potential risks, uncertainties, and other important factors in Autolus'
subsequent filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release, and
Autolus undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, or
otherwise, except as required by law.

 

Contact:

 

Olivia Manser

+44 (0) 7780 471568

o.manser@autolus.com (mailto:o.manser@autolus.com)

 

Julia Wilson

+44 (0) 7818 430877

j.wilson@autolus.com (mailto:j.wilson@autolus.com)

 

Susan A. Noonan

S.A. Noonan Communications

+1-917-513-5303

susan@sanoonan.com (mailto:susan@sanoonan.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PFUFFFIIFVLTIIF